Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

• Váldodahkkit: Hui-Yao Huang (Dahkki), Cheng-Cheng Liu (Dahkki), Yue Yu (Dahkki), Le Wang (Dahkki), Da-Wei Wu (Dahkki), Lan-Wei Guo (Dahkki), Shu-Hang Wang (Dahkki), Hong Fang (Dahkki), Ying Bai (Dahkki), Yuan Fang (Dahkki), Qi Fan (Dahkki), Chao Sun (Dahkki), Ying Wu (Dahkki), Ju-Fang Shi (Dahkki), Fei Ma (Dahkki), Yu Tang (Dahkki), Min Dai (Dahkki), Ning Li (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background and Purpose: The availability of oncology biosimilars is deemed as a fundamental strategy to achieve sustainable health care. However, there is scarce systematic evidence on economic effectiveness of cancer biosimilars. We aimed to synthesize evidence from pharmacoeconomic evaluation of o...